NASDAQ:GTH

Genetron (GTH) Stock Forecast, Price & News

$0.89

+0.01 (+1.43%)

(As of 12:21 PM ET)

Compare

Today's Range: $0.87
▼
$0.89
50-Day Range: $0.87
▼
$1.06
52-Week Range: $0.73
▼
$1.75

Volume: 25,615 shs
Average Volume: 61,660 shs
Market Capitalization: $81.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Genetron (NASDAQ:GTH) Stock

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Receive GTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetron and its competitors with MarketBeat's FREE daily newsletter.

GTH Stock News Headlines

May 31, 2023 | americanbankingnews.com

Genetron (NASDAQ:GTH) Trading Down 3.3%

May 24, 2023 | msn.com

Genetron Health receives Nasdaq notice for non-compliance

June 5, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.

April 19, 2023 | americanbankingnews.com

Short Interest in Genetron Holdings Limited (NASDAQ:GTH) Expands By 41.6%

March 27, 2023 | msn.com

American Depositary Receipts of Asian Stocks Lower Amid Banking Sector Worries

January 18, 2023 | finance.yahoo.com

Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement

December 28, 2022 | msn.com

Earlier US Stock Market Losses Weighed on Asian Equities

November 7, 2022 | finance.yahoo.com

Genetron Health Announces Receipt of Notification from Nasdaq

June 5, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

October 19, 2022 | seekingalpha.com

GTH Genetron Holdings Limited

October 12, 2022 | finance.yahoo.com

Genetron Health Reports Unaudited Second Quarter 2022 Financial Results

September 20, 2022 | reuters.com

Genetron Holdings Ltd

September 2, 2022 | finance.yahoo.com

Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

August 22, 2022 | benzinga.com

Genetron Health Announces Receipt of a...

August 22, 2022 | nasdaq.com

Genetron Health Board Receives Proposal Letter From CEO Sizhen Wang

August 19, 2022 | finance.yahoo.com

Strong week for Genetron Holdings (NASDAQ:GTH) shareholders doesn't alleviate pain of one-year loss

June 15, 2022 | seekingalpha.com

Genetron's Maryland lab gets CAP accreditation

June 15, 2022 | finance.yahoo.com

Genetron Health Receives CAP Accreditation for its Maryland Laboratory

June 3, 2022 | markets.businessinsider.com

COO Boosts Revenue Outlook, GTH On Watch, PHR Forecasts 27% To 29% Revenue Growth...

June 2, 2022 | seekingalpha.com

Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2022 Results - Earnings Call Transcript

June 2, 2022 | finance.yahoo.com

Genetron Health Reports Unaudited First Quarter 2022 Financial Results

June 1, 2022 | seekingalpha.com

China's Genetron's gene mutation test FusionScan gets CE mark in EU

May 23, 2022 | finance.yahoo.com

Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

April 7, 2022 | stockhouse.com

Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule(TM)'s potential in MRD Assay Developments

April 7, 2022 | finance.yahoo.com

Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™’s potential in MRD Assay Developments

March 30, 2022 | markets.businessinsider.com

IMAB On Watch, GTH Expects 2022 Revenue To Grow 10-20%, PHVS To Report HAE Trial Data In Q4

March 29, 2022 | finance.yahoo.com

Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

See More Headlines

GTH Price History

30 days | 90 days | 365 days | Advanced Chart

GTH Company Calendar

Last Earnings: 5/23/2021
Today: 6/05/2023
Next Earnings (Estimated): 6/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GTH
CUSIP: N/A
CIK: 1782594
Web: www.genetronhealth.com
Phone: 86-10-5090-7500
Fax: N/A
Employees: 1,154
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 1.82
Quick Ratio: 1.71

Sales & Book Value

Annual Sales: $650.71 million
Price / Sales: 0.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.88 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 91,549,000
Free Float: N/A
Market Cap: $80.64 million
Optionable: Not Optionable
Beta: 0.53

Key Executives

Mr. Sizhen Wang (Age 46)
Co-Founder, CEO & Chairman

Dr. Wei-Wu He Ph.D. (Age 58)
Co-Founder & Chairman Emeritus

Dr. Hai Yan (Age 55)
Co-Founder, Chief Scientific Officer & Director

Mr. Ce Xu (Age 41)
Chief Financial Officer

Ms. Victoria Lei
Chief Operating Officer

Dr. Yuchen Jiao M.D. (Age 45)
Ph.D., Chief Technology Officer

Mr. Yong Liang (Age 49)
Chief HR Officer

Dr. Yun-Fu Hu Ph.D. (Age 60)
Chief Medical Officer

Ms. Lily Liu
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GTH Stock - Frequently Asked Questions

How have GTH shares performed in 2023?: Genetron's stock was trading at $1.12 at the start of the year. Since then, GTH shares have decreased by 21.4% and is now trading at $0.8808.
View the best growth stocks for 2023 here.
Are investors shorting Genetron?: Genetron saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 158,600 shares, a decline of 8.3% from the April 30th total of 172,900 shares. Based on an average daily volume of 28,200 shares, the days-to-cover ratio is presently 5.6 days. Currently, 0.2% of the company's shares are short sold.
View Genetron's Short Interest.
When is Genetron's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 6th 2023.
View our GTH earnings forecast.
How were Genetron's earnings last quarter?: Genetron Holdings Limited (NASDAQ:GTH) posted its quarterly earnings data on Sunday, May, 23rd. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.10. The firm had revenue of $14.05 million for the quarter.
Read the conference call transcript.
When did Genetron IPO?: (GTH) raised $162 million in an initial public offering on Friday, June 19th 2020. The company issued 13,000,000 shares at a price of $11.50-$13.50 per share. Credit Suisse and CICC acted as the underwriters for the IPO and BTIG and Canaccord Genuity were co-managers.
What is Genetron's stock symbol?: Genetron trades on the NASDAQ under the ticker symbol "GTH."

Who are Genetron's major shareholders?: Genetron's stock is owned by a number of retail and institutional investors. Top institutional investors include Hudson Bay Capital Management LP (0.54%), Schonfeld Strategic Advisors LLC (0.17%) and Susquehanna International Group LLP (0.04%).
How do I buy shares of Genetron?: Shares of GTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Genetron's stock price today?: One share of GTH stock can currently be purchased for approximately $0.88.
How much money does Genetron make?: Genetron (NASDAQ:GTH) has a market capitalization of $80.64 million and generates $650.71 million in revenue each year. The company earns $-117,210,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.
How many employees does Genetron have?: The company employs 1,154 workers across the globe.
How can I contact Genetron?: Genetron's mailing address is 1-2/F BUILDING 11 ZONE 1 CHANGPING DISTRICT, BEIJING F4, 102206. The official website for the company is www.genetronhealth.com. The company can be reached via phone at 86-10-5090-7500 or via email at ir@genetronhealth.com.

This page (NASDAQ:GTH) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial